Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

22 april 2019 | Bron: Reuters Health

The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

Lees verder op: Reuters Health